A new polyglutamic acid-PTX-NCAM Targeting Peptide (PGA-PTX-NTP) conjugate was developed and evaluated experimentally in neuroblastoma in vivo, and showed improvement in the NCAM-targeted tumor cell killing rate, prolonged drug action time and reduction of toxic effects (Kiselyov et al., 2009; Markovsky et al., 2017). The gene discussed is NCAM1; the disease is neuroblastoma.